Dapagliflozin cardiovascular effects on end-stage kidney disease (DARE-ESKD-2) trial: rationale and design.

Joaquim Barreto, Marilia Martins,Mauro Pascoa,Sheila T K Medorima,Isabella Bonilha, Daniel Campos Jesus,Cinthia E M Carbonara,Kelcia R S Quadros,Barbara Assato,Alessandra M Campos-Staffico,Gil Guerra Júnior,Wilson Nadruz,Rodrigo B de Oliveira,Andrei C Sposito

Research square（2023）

引用 0|浏览5

暂无评分

摘要

The DARE-ESKD-2 trial will provide unprecedented data on the cardiovascular safety and efficacy of SGLT2i in ESKD individuals on dialysis. This study will pave the grounds for improving clinical outcomes of dialysis recipients.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要